Tumor Biology

, Volume 37, Issue 10, pp 14193–14203 | Cite as

Downregulation of paraoxonase 3 contributes to aggressive human hepatocellular carcinoma progression and associates with poor prognosis

  • Yuepeng Jin
  • Qiang Li
  • Junjun Qiu
  • Xiufen Zhao
  • Chunxiao Zheng
  • Shixu Lv
  • Yongyu Bai
  • Yunfeng Shan
  • Le-chi Ye
Original Article


Paraoxonase (PON) enzymes possess antioxidant properties and protect against cardiovascular diseases. As a member of PON family, PON3 is primarily synthesized in the liver and poorly investigated. This study aimed to examine the expression of PON3 in human hepatocellular carcinoma (HCC) and investigate the clinical significance and biological function of PON3 in HCC patients. We first analyzed PON3 expression in 50 paired HCC samples (HCC tissues vs matched para-cancerous tissues) and 160 clinical HCC specimens by using immunohistochemistry (IHC). Our results showed that the expression of PON3 was downregulated in HCC and significantly associated with tumor-node-metastasis (TNM) stage, tumor size, and tumor number. Kaplan-Meier survival and Cox regression analyses showed that PON3 was an independent prognostic factor for overall survival (OS) and time to recurrence (TTR). Finally, we aimed to reveal the biological function of PON3 in HCC growth and metastasis, and our results showed that overexpression of PON3 potently inhibited growth and metastasis of HCC. Collectively, our study demonstrated that PON3 exhibited tumor-suppressive effects toward HCC and it might serve as a novel prognostic marker in HCC.


Paraoxonase 3 Hepatocellular carcinoma Prognosis Growth Metastasis 



This study was supported by grants from Zhejiang Provincial Natural Science Foundation of China (nos. LY12H03006 and LY15H160058) and the National Natural Science Foundation of China (no. 81572291).

Compliance with ethical standards

Conflicts of interest


Supplementary material

13277_2016_5247_MOESM1_ESM.jpg (160 kb)
Supplementary Figure 1 Analysis for protein levels of PON3 in HCC cell lines. Protein levels of PON3 were determined by Western Blot in six HCC cell lines and one immortalized liver cell line. (JPG 159 kb)


  1. 1.
    Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMedGoogle Scholar
  2. 2.
    Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379:1245–55.CrossRefPubMedGoogle Scholar
  3. 3.
    Tsoulfas G, Kawai T, Elias N, et al. Long-term experience with liver transplantation for hepatocellular carcinoma. J Gastroenterol. 2011;46:249–56.CrossRefPubMedGoogle Scholar
  4. 4.
    Bruix J, Gores GJ, Mazzaferro V. Hepatocellular carcinoma: clinical frontiers and perspectives. Gut. 2014;63:844–55.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Thomas MB, Zhu AX. Hepatocellular carcinoma: the need for progress. J Clin Oncol. 2005;23:2892–9.CrossRefPubMedGoogle Scholar
  6. 6.
    Ueno M, Uchiyama K, Ozawa S, et al. Adjuvant chemolipiodolization reduces early recurrence derived from intrahepatic metastasis of hepatocellular carcinoma after hepatectomy. Ann Surg Oncol. 2011;18:3624–31.CrossRefPubMedGoogle Scholar
  7. 7.
    Bergmeier C, Siekmeier R, Gross W. Distribution spectrum of paraoxonase activity in HDL fractions. Clin Chem. 2004;50:2309–15.CrossRefPubMedGoogle Scholar
  8. 8.
    Li HL, Liu DP, Liang CC. Paraoxonase gene polymorphisms, oxidative stress, and diseases. J Mol Med (Berl). 2003;81:766–79.CrossRefGoogle Scholar
  9. 9.
    Shih DM, Xia YR, Yu JM, et al. Temporal and tissue-specific patterns of Pon3 expression in mouse: in situ hybridization analysis. Adv Exp Med Biol. 2010;660:73–87.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Précourt LP, Amre D, Denis MC, et al. The three-gene paraoxonase family: physiologic roles, actions and regulation. Atherosclerosis. 2011;214:20–36.CrossRefPubMedGoogle Scholar
  11. 11.
    Reddy ST, Devarajan A, Bourquard N, et al. Is it just paraoxonase 1 or are other members of the paraoxonase gene family implicated in atherosclerosis? Curr Opin Lipidol. 2008;19:405–8.CrossRefPubMedGoogle Scholar
  12. 12.
    Ng CJ, Shih DM, Hama SY, et al. The paraoxonase gene family and atherosclerosis. Free Radic Biol Med. 2005;38:153–63.CrossRefPubMedGoogle Scholar
  13. 13.
    Ng CJ, Bourquard N, Hama SY, et al. Adenovirus-mediated expression of human paraoxonase 3 protects against the progression of atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2007;27:1368–74.CrossRefPubMedGoogle Scholar
  14. 14.
    Reddy ST, Wadleigh DJ, Grijalva V, et al. Human paraoxonase-3 is an HDL-associated enzyme with biological activity similar to paraoxonase-1 protein but is not regulated by oxidized lipids. Arterioscler Thromb Vasc Biol. 2001;21:542–7.CrossRefPubMedGoogle Scholar
  15. 15.
    Shih DM, Xia YR, Wang XP, et al. Decreased obesity and atherosclerosis in human paraoxonase 3 transgenic mice. Circ Res. 2007;100:1200–7.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Mackness M, Mackness B. Human paraoxonase-1 (PON1): gene structure and expression, promiscuous activities and multiple physiological roles. Gene. 2015;567:12–21.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Rajaraman P, Hutchinson A, Rothman N, et al. Oxidative response gene polymorphisms and risk of adult brain tumors. Neuro Oncol. 2008;10:709–15.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Schwarzer C, Fu Z, Morita T, et al. Paraoxonase 2 serves a proapopotic function in mouse and human cells in response to the Pseudomonas aeruginosa quorum-sensing molecule N-(3-Oxododecanoyl)-homoserine lactone. J Biol Chem. 2015;290:7247–58.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Witte I, Altenhöfer S, Wilgenbus P, et al. Beyond reduction of atherosclerosis: PON2 provides apoptosis resistance and stabilizes tumor cells. Cell Death Dis. 2011;2:e112.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Choi JK, Choi JY, Kim DG, et al. Integrative analysis of multiple gene expression profiles applied to liver cancer study. FEBS Lett. 2004;565:93–100.CrossRefPubMedGoogle Scholar
  21. 21.
    Santin AD, Zhan F, Bellone S, et al. Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy. Int J Cancer. 2004;112:14–25.CrossRefPubMedGoogle Scholar
  22. 22.
    Schweikert EM, Devarajan A, Witte I, et al. PON3 is upregulated in cancer tissues and protects against mitochondrial superoxide-mediated cell death. Cell Death Differ. 2012;19:1549–60.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Jin H, Zhang Y, You H, et al. Prognostic significance of kynurenine 3-monooxygenase and effects on proliferation, migration, and invasion of human hepatocellular carcinoma. Sci Rep. 2015;5:10466.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Zhu AX. Systemic treatment of hepatocellular carcinoma: dawn of a new era? Ann Surg Oncol. 2010;17:1247–56.CrossRefPubMedGoogle Scholar
  25. 25.
    Siddiqui NN, Ul Haq A, Siddiqui OA, Khan R, et al. DNA methyltransferase 1, 3a, and 3b expression in hepatitis C associated human hepatocellular carcinoma and their clinicopathological association. Tumour Biol. 2016. doi: 10.1007/s13277-016-4941-1
  26. 26.
    Shi W, Huang W, Chen Y, et al. Low expression of PIDD is associated with cell proliferation and apoptosis in hepatocellular carcinoma. Tumour Biol. 2016. doi: 10.1007/s13277-015-4556-y
  27. 27.
    Chen W, Chen L, Cai Z, et al. Overexpression of annexin A4 indicates poor prognosis and promotes tumor metastasis of hepatocellular carcinoma. Tumour Biol. 2016. Jul;37(7):9343-55Google Scholar
  28. 28.
    Li Y, Li Y, Tang R, et al. Discovery and analysis of hepatocellular carcinoma genes using cDNA microarrays. J Cancer Res Clin Oncol. 2002;128:369–79.CrossRefPubMedGoogle Scholar
  29. 29.
    Ribarska T, Ingenwerth M, Goering W, et al. Epigenetic inactivation of the placentally imprinted tumor suppressor gene TFPI2 in prostate carcinoma. Cancer Genomics Proteomics. 2010;7:51–60.PubMedGoogle Scholar
  30. 30.
    Witte I, Foerstermann U, Devarajan A, et al. Protectors or traitors: the roles of PON2 and PON3 in atherosclerosis and cancer. J Lipids. 2012;2012:342806.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Ross ME, Zhou X, Song G, et al. Classification of pediatric acute lymphoblastic leukemia by gene expression profiling. Blood. 2003;102:2951–9.CrossRefPubMedGoogle Scholar
  32. 32.
    Kang H, Chen IM, Wilson CS, et al. Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor acute lymphoblastic leukemia. Blood. 2010;115:1394–405.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Draganov DI, Stetson PL, Watson CE, et al. Rabbit serum paraoxonase 3 (PON3) is a high density lipoprotein-associated lactonase and protects low density lipoprotein against oxidation. J Biol Chem. 2000;275:33435–42.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2016

Authors and Affiliations

  • Yuepeng Jin
    • 1
  • Qiang Li
    • 2
  • Junjun Qiu
    • 3
  • Xiufen Zhao
    • 1
  • Chunxiao Zheng
    • 1
  • Shixu Lv
    • 3
  • Yongyu Bai
    • 2
  • Yunfeng Shan
    • 1
  • Le-chi Ye
    • 4
  1. 1.Department of General Surgery, The First Affiliated HospitalWenzhou Medical UniversityWenzhouChina
  2. 2.Wenzhou Medical UniversityWenzhouChina
  3. 3.Department of Gynecology, Obstetrics and Gynecology HospitalFudan UniversityShanghaiChina
  4. 4.Department of Oncological SurgeryThe First Affiliated Hospital of Wenzhou Medical UniversityWenzhouChina

Personalised recommendations